Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
申请人:STATegics, Inc.
公开号:US09163027B2
公开(公告)日:2015-10-20
Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.
本文披露了公式I的类似促红细胞生成素化合物,它们可以调节肾细胞、神经元、红细胞或其他对促红细胞生成素敏感的细胞的生存、功能或分化。本发明还涉及优先调节表达组织保护性促红细胞生成素受体的细胞的化合物和方法。本发明的化合物可用于预防和治疗贫血、器官损伤和中枢神经系统疾病,并作为细胞治疗(如干细胞治疗)的辅助治疗。